Market Overview

UPDATE: Credit Suisse Downgrades Vivus on Valuation

Related VVUS
Orexigen Therapeutics Gains On Diet Pill Nod From European Committee
Pharmaceutical Stocks In Play Following Merck/Cubist Deal

In a report published Monday, Credit Suisse analyst Lee Kalowski downgraded the rating on Vivus (NASDAQ: VVUS) from Outperform to Neutral, but reiterated the $15.00 price target.

In the report, Credit Suisse noted, “We are downgrading VVUS from Outperform to Neutral on valuation. It is looking increasingly likely to us that at least some level of board/management changes are inevitable. But with the stock trading at close to $15, we think investors are increasingly pricing this in. Upside from here would likely require an outright sale, which we see as unlikely.”

Vivus closed on Friday at $14.70.

Latest Ratings for VVUS

DateFirmActionFromTo
Nov 2014Bank of AmericaMaintainsUnderperform
May 2014JP MorganMaintainsNeutral
Apr 2014Piper JaffrayDowngradesNeutralUnderweight

View More Analyst Ratings for VVUS
View the Latest Analyst Ratings

Posted-In: Credit Suisse Lee KalowskiAnalyst Color Downgrades Analyst Ratings

 

Related Articles (VVUS)

Around the Web, We're Loving...

Get Benzinga's Newsletters